Rebiotix Inc., a subsidiary of Ferring Pharmaceuticals, is a pioneering company based in Roseville, Minnesota, dedicated to harnessing the power of the microbiome to address debilitating diseases. With a strong focus on microbiome-based technologies, Rebiotix has achieved significant milestones, including FDA approval of a first-in-class live biotherapeutic product for preventing C. difficile infection recurrence.
As a global leader in microbiome-based therapeutics and research, Rebiotix, in collaboration with Ferring Pharmaceuticals, is committed to improving the lives of individuals worldwide. Through innovative technologies and a passion for microbiome research, the company aims to tackle some of the most pressing healthcare challenges of our time.
Generated from the website